The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs. - Li YC; Lin BH; Murakami M; Wu YS; Hung TH; Ambudkar SV; Wu CP (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2025)